

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026372 A1

(51) International Patent Classification⁷: **C12N 15/88**,
C07C 321/14, 235/06, 271/16, 275/06, A61K 9/127,
47/48, 48/00, 31/7088, 47/44, C07H 21/00

(21) International Application Number:
PCT/CA2004/001677

(22) International Filing Date:
15 September 2004 (15.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/503,239 15 September 2003 (15.09.2003) US

(71) Applicant (for all designated States except US): **PRO-
TIVA BIOTHERAPEUTICS, INC.** [CA/CA]; 100-3480
Gilmore Way, Burnaby, British Columbia V5G 4Y1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEYES, James**

[GB/CA]; 315-651 Moberly Road, Vancouver, British Co-
lumbia V5Z 4B2 (CA). **MACLACHLAN, Ian** [GB/CA];
1514 Grant Street, Vancouver, British Columbia V5L 2Y2
(CA). **AMBEGIA, Ellen Grace** [CA/CA]; 3150 W. 4th
Ave, #302, Vancouver, British Columbia V6K 1R7 (CA).

(74) Agents: **FETHERSTONHAUGH & CO.** et al.; Box
11560, Suite 2200, 650 West Georgia Street Vancouver,
British Columbia V6B 4N8 (CA).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,


[Continued on next page]

(54) Title: POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF


N-(2,3-dimyristyloxypropyl) amide PEG₂₀₀₀ methyl ether (PEG-A-DMA)



N-(2,3-dimyristyloxypropyl) carbamate PEG₂₀₀₀ methyl ether (PEG-C-DMA)



N-(2,3-dimyristyloxypropyl) succinamide PEG₂₀₀₀ methyl ether (PEG-S-DMA)



(57) Abstract: Polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates are disclosed which have increased stability over commonly used PEG-lipids conjugates. Liposomal compositions, stabilized plasmid-lipid particles (SPLP) and stabilized nucleic acid-lipid particles (SNALP) comprising said PEG-DAA conjugates, for delivery of a bioactive agent to a cell or patient are described.

WO 2005/026372 A1



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.